Active Ingredient(s): Ezogabine
FDA Approved: * June 10, 2011
Pharm Company: * VALEANT PHARMA
Category: Anticonvulsant

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Potiga Overview

Retigabine (INN) or ezogabine (USAN) is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.[2] The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011. Production has been discontinued in June 2017.&a...

Read more Potiga Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Retigabine

Recent Potiga Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 200mg, 300mg, 400mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Potiga: (4 results)

Sorted by National Drug Code
  • 0173-0810 Potiga 50 mg Oral Tablet by Glaxosmithkline LLC
  • 0173-0812 Potiga 200 mg Oral Tablet by Glaxosmithkline LLC
  • 0173-0813 Potiga 300 mg Oral Tablet by Glaxosmithkline LLC
  • 0173-0814 Potiga 400 mg Oral Tablet by Glaxosmithkline LLC

Other drugs which contain Ezogabine or a similar ingredient: (1 result)